Putting the award page together from the records…
Putting the award page together from the records…
Novartis Pharmaceuticals Corporation received this contract from 262-Network Contract Office 22 (36C262), Department of Veterans Affairs: $1.65M obligated so far for drugs and biologicals. It runs to 2027-01-01, or to 2031-01-01 if every option is exercised.
Key facts · data as of Oct 23, 2026
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 23, 2026.
Cite this page: SpendQuery, Award 36C26226F0048, data as of Oct 23, 2026, https://spendquery.com/award?id=CONT_AWD_36C26226F0048_3600_36F79720D0180_3600
Novartis Pharmaceuticals Corporation: all federal awards · Department of Veterans Affairs: spending · 262-Network Contract Office 22 (36C262): what it buys · The follow-on: recompete brief
PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML)
Up for re-bid: ends 2027-01-01. Recompete brief → · 6505--VA GLA Pluvicto and Lutathera ↗
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
3 actions since 2025-12-30. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-17 | P00002 | Funding only | $623.1K | PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML) |
| 2026-01-20 | P00001 | Supplemental agreement (work within scope) | $0 | PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML) |
| 2025-12-30 | 0 | $1.02M | PLUVICTO (LUTETIUM LU 177 VIPIVOTIDE TETRA 27MCI/ML) |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-23). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗